Clinical trials: Athlete Foot
Tinea Pedis
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and…
- Trial name
- NCT03999437
- Testing
- TERBINAFINE HYDROCHLORIDE (1%), BUTENAFINE HYDROCHLORIDE (1%), Vehicle Control
- Where
- Philippines
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- United Laboratories
Tinea Pedis
Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis
The aim of this study is to determine the efficacy and safety of a topical application of the combinational cream LAS41003 compared to application of its mono-substances after once daily treatment in patients with inflammatory…
- Trial name
- NCT01096472
- Testing
- LAS41003, LAS189961, LAS189962
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Almirall, S.A.
Tinea Pedis
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with…
- Trial name
- NCT01580878
- Testing
- Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle
- Volunteers
- 707 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of…
- Trial name
- NCT02842021
- Testing
- S2G6T-1, S2G6T-2, S2G6T-3
- Where
- 19 sites in United States
- Volunteers
- 283 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Tinea Pedis, Tinea Cruris
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence…
- Conditions
- Tinea Pedis, Tinea Cruris, Tinea Corporis
- Trial name
- NCT01349998
- Testing
- Product 33525
- Where
- 24 sites in United States, Belize and 3 more
- Volunteers
- 604 people
- Sponsor
- Tinea Pharmaceuticals
Tinea Pedis
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
The study is being done to determine and compare the safety and effectiveness of an investigational combination therapy (low and high concentrations) versus mono-therapy (low and high concentrations) or mono-therapy (fixed…
- Trial name
- NCT03897257
- Testing
- UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- Therapeutics, Inc.
Tinea Pedis
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or 28 days to achieve "complete clearance" at 2 weeks post treatment.
- Trial name
- NCT00869336
- Testing
- Luliconazole Cream 1% - 2 wks, Luliconazole Cream 1% - 4 wks
- Where
- 4 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tinea Pharmaceuticals
Tinea Pedis
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
- Trial name
- NCT03824912
- Testing
- Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.)
- Where
- 9 sites in United States, Belize and 1 more
- Volunteers
- 831 people
- Sponsor
- Encube Ethicals Pvt. Ltd.
Onychomycosis/Onycholysis and Tinea Pedis
Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis
In this study, the safety and pharmacokinetics of 10 % terbinafine hydrogen chloride (HCl) nail lacquer wre investigated by comparison with vehicle control and 1% terbinafine cream
- Trial name
- NCT00691184
- Testing
- Terbinafine Hydrochloride, Terbinafine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Tinea Pedis
Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo
The study shall prove whether 6 consecutive doses of Bifonazole spray show comparable efficacy to a Terbinafine solution applied once.
- Trial name
- Porsche (NCT01013909)
- Testing
- Bifonazole spray once daily, Bifonazole spray twice daily, Lamisil Once
- Where
- 4 sites in Germany
- Volunteers
- 220 people
- Sponsor
- Bayer
Tinea Pedis, Athlete's Foot
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
This is a study of the safety and efficacy of Econazole Nitrate Foam 1% and the Foam Vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes).
- Trial name
- NCT01358240
- Testing
- Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%
- Where
- 12 sites in United States
- Volunteers
- 336 people
- Sponsor
- AmDerma
Tinea Pedis
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
This is a non-inferiority, Phase III, open-label, randomized, parallel trial to evaluate the new intervention Dapaconazole cream 2% versus Ketoconazole cream 2% in patients with Tinea pedis.
- Trial name
- NCT02606383
- Testing
- Dapaconazole, Ketoconazole
- Where
- Brazil
- Sponsor
- Biolab Sanus Farmaceutica
Tinea Pedis
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
- Trial name
- NAFT-600 (NCT01290341)
- Testing
- NAFT-600 (naftin 2 % gel)
- Where
- 23 sites in United States
- Volunteers
- 860 people
- Sponsor
- Merz North America, Inc.
Tinea Pedis
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
This is an open-label, single-dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis.
- Trial name
- NCT04152226
- Testing
- Janthinobacterium lividum
- Where
- Dominican Republic
- Volunteers
- 12 people
- Sponsor
- DermBiont, Inc.
Tinea Cruris, Tinea Pedis
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris…
- Trial name
- NCT05363449
- Testing
- UHE-103 Cream, Naftin (naftifine hydrochloride) Cream
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Therapeutics, Inc.
Tinea Pedis
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
- Trial name
- NCT04883593
- Testing
- TA103
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis
A multi-arm trial to evaluate the efficacy and safety of using gaseous nitric oxide to treat moderate to severe tinea pedis.
- Trial name
- NCT00893880
- Testing
- 1% gaseous Nitric Oxide blended in Oxygen
- Where
- 4 sites in Canada, Saint Kitts and Nevis
- Volunteers
- 92 people
- Sponsor
- Nitric BioTherapeutics, Inc
Tinea Pedis, Tinea Cruris
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch.
- Trial name
- NCT01712360
- Testing
- NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult)
- Where
- 4 sites in United States, Dominican Republic and 1 more
- Volunteers
- 56 people
- Sponsor
- Merz North America, Inc.
Tinea Pedis
BE Study of Naftifine HCL
The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details.
- Trial name
- NCT02633813
- Testing
- Naftifine hydrochloride 2%, Naftin® 2% (Naftifine hydrochloride 2%)
- Where
- 14 sites in United States, Dominican Republic
- Volunteers
- 693 people
- Sponsor
- Genzum Life Sciences
Tinea Pedis
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
A prospective, open post-market clinical investigation that will enroll male and female subjects diagnosed with foot fungus and at least one of the following conditions: heal cracks, calluses and/or dry feet.
- Trial name
- NCT03676686
- Testing
- Nåva Foot Cream
- Where
- 3 sites in Sweden
- Volunteers
- 46 people
- Sponsor
- Natumin Pharma AB